Plus, news about Retension Pharmaceuticals:
Vandria tops up Series A with another $10M: The Swiss biotech increased its round total to $30.7 million after getting a new investment from the Hevolution Foundation and Dolby Family Ventures. Vandria is developing what it calls “mitophagy inducers” against an undisclosed target to try to treat age-related and chronic diseases. — Max Gelman
Nykode Therapeutics repositions cancer vaccine: The Norwegian biotech is prioritizing the development of VB10.16 for locally advanced cervical cancer and recurrent metastatic head and neck cancer. As part of this decision, Nykode is terminating a Phase 2 trial of the candidate in second-line cervical cancer. — Ayisha Shama
Retension Pharmaceuticals secures $10.4M in Series A: The proceeds from the oversubscribed fundraise will be put toward a Phase 2 trial of the biotech’s lead hypertension candidate, RTN-001. The second-generation PDE5 inhibitor is designed to target the tissues in the higher vasculature. — Ayisha Shama